Overview

Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: A randomized, multi-center, double-blind, phase 3 study
Phase:
Phase 3
Details
Lead Sponsor:
IlDong Pharmaceutical Co Ltd
Treatments:
Fenofibrate
Rosuvastatin Calcium